Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho; Delvys Rodríguez‐Abreu; Maen Hussein; Manuel Cobo; A. Patel; Nevena Sečen; Ki Hyeong Lee; Bartomeu Massutí; Sandrine Hiret; James Chih Hsin Yang; Fabrice Barlési; Dae Ho Lee; Luis Paz Ares; Robert W. Hsieh; Namrata S. Patil; Patrick J. Twomey; Xiaoying Yang; Raymond D. Meng; Melissa L. Johnson

doi:10.1016/s1470-2045(22)00226-1

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | Litlas